CHAARTED
2015
ADT + Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
In 790 patients with metastatic hormone-sensitive prostate cancer, ADT + docetaxel improved overall survival compared with ADT alone.
Result
Efficacy: Overall survivalHR 0.61
Below 1 favours ADT + docetaxel, above 1 favours ADT alone.
Event rates ADT + docetaxel 57.6 vs ADT alone 44.0 months
Also reported: High-volume subgroup: 51.2 vs 34.4 months (HR 0.63). No clear benefit in low-volume at long-term follow-up.
- Subtopic
- mHSPC
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Sweeney CJ, et al. N Engl J Med. 2015;373(8):737-746; Kyriakopoulos CE, et al. J Clin Oncol. 2018;36(11):1080-1087.doi 10.1056/NEJMoa1503747
Discussion & critique
Opened the era of intensification on top of ADT in mHSPC. STAMPEDE/LATITUDE and triplet regimens (ARASENS, PEACE-1) have built on this scaffold.